Tuberculosis is still a deadly killer, and a new report by two humanitarian organisations raises alarm on poor progress on the disease diagnosis and treatment. The report calls for governments to increase efforts to fight the disease, and for the G20 countries to mobilise funds to help, in particular to boost research and development for new treatments. Separately, the World Health Organization issued a call for new treatments to fight antibiotic resistant gonorrhoea. Continue reading ->
For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading ->
Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Continue reading ->
Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading ->